MFTZ-1, an actinomycetes subspecies-derived antitumor macrolide, functions as a novel topoisomerase II poison

Molecular Cancer Therapeutics

Volumn 6, Issue 11, 2007, Pages 3059-3070

  Xie, Cheng Ying ^a   Zhu, Hong ^a   Lin, Li Ping ^a   Miao, Ze Hong ^a   Geng, Mei Yu ^a   Cai, Yu Jun ^a   Chen, Yi ^a   Zhao, Hua Jun ^a   Luo, Hai Bin ^a   Zhang, Xiong Wen ^a   Fan, Li Ming ^b   Shen, Yue Mao ^b   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b KUNMING INSTITUTE OF BOTANY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

14 ETHYL 2,5,11 TRIMETHYL 4,13,19,20 TETRAOXA TRICYCLO[14.2.1.1 7,10]EICOSANE 3,12 DIONE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; MACROLIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ACTINOBACTERIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LEUKEMIA CELL; MITOCHONDRION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; STREPTOMYCES; TUMOR CELL LINE; XENOTRANSPLANTATION;

ACTINOBACTERIA; ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DNA BREAKS, DOUBLE-STRANDED; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; EICOSANOIDS; FEMALE; HUMANS; INTERCALATING AGENTS; MACROLIDES; MICE; MITOCHONDRIA; SACCHAROMYCES CEREVISIAE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 36749050957     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0014     Document Type: Article

References (48)

1. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
2. Walker J, Nitiss JL. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 2002;20:570-89.
3. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-75.
4. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:139-54.
5. Rezanka T, Spizek J, Prikrylova V, Prell A, Dembitsky VM. Five new derivatives of nonactic and homo-nonactic acids from Streptomyces globisporus. Tetrahedron 2004;60:4781-7.
6. Stastna J, Goodfellow M, Kristufek V, et al. Characteristics of Streptomyces globisporus strain 0234A formingen dospores in submerged cultures. Folia Microbiol 1992;37:111-6.
7. Bennett RE, Brindle SA, Giuffre NA, et al. Production of a novel cytotoxic agent, SQ 15,859, by Streptomyces chrysomallus. Antimicrob Agents Chemother 1961;1:169-72.
8. Borrel MN, Pereira E, Fiallo M, Garnier-Suillerot A. Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4′-O-tetrahydropyranyl-Adriamycin incorporation in K562 drug-resistant cells. Eur J Biochem 1994;223:125-33.
9. Zhao PJ, Fan LM, Li GH, Zhu N, Shen YM. Antibacterial and antitumor macrolides from Streptomyces sp. ls9131. Arch Pharm Res 2005;28:1228-32.
10. Yang CZ, Luan FJ, Xiong DS, Liu BR, Xu YF, Gu KS. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin. Zhongguo Yao Li Xue Bao 1995;16:333-7.
11. Fairchild CR, Moscow JA, O'Brien EE, Cowan KH. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-π. Mol Pharmacol 1990;37:801-9.
12. Cowan KH, Batist G, Tulpule A, Sinha BK, Myers CE. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci 1986;83:9328-32.
13. Zhang XH, Zhang FY, Ji XJ, Li ZY. Vincristine-resistant human KB cell line and mechanism of multidrugresist ance. Yao Xue Xue Bao 1994;29:246-51.
14. Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci 1988;85:7501-5.
15. Binaschi M, Farinosi R, Austin CA, Fisher LM, Zunino F, Capranico G. Human DNA topoisomerase IIa-dependent DNA cleavage and yeast cell killingby anthracycline analogues. Cancer Res 1998;58:1886-92.
16. Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the antitopoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Cancer 2003;106:108-15.
17. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "Comet" assay. Radiat Res 1990;122:86-94.
18. Lu HR, Meng LH, Huang M, Zhu H, Miao ZH, Ding J. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells. Cancer Chemother Pharmacol 2005;55:286-94.
19. Steinfelder HJ, Quentin I, Ritz V. A fast and sensitive technique to study the kinetics and the concentration dependencies of DNA fragmentation duringdrug -induced apoptosis. J Pharmacol Toxicol Methods 2000;43:79-84.
20. Osheroff N, Shelton ER, Brutlag DL. DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA. J Biol Chem 1983;258:9536-43.
21. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991;51:4903-8.
22. Willmore E, Frank AJ, Padget K, Tilby MJ, Austin CA. Etoposide targets topoisomerase IIa and IIh in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol 1998;54:78-85.
23. Yamashita Y, Fujii N, Murakata C, Ashizawa T, Okabe M, Nakano H. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 1992;31:12069-75.
24. Hu CX, Zuo ZL, Xiong B, et al. Salvicine functions as a novel topoisomerase II poison by bindingto ATP pocket. Mol Pharmacol 2006;70:1593-601.
25. Amarante-Mendes GP, Finucane DM, Martin SJ, Cotter TG, Salvesen GS, Green DR. Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death. Cell Death Differ 1998;5:298-306.
26. Miura K, Aminova L, Murayama Y. Fusarenon-X induced apoptosis in HL-60 cells depends on caspase activation and cytochrome c release. Toxicology 2002;172:103-12.
27. Coultas L, Strasser A. The molecular control of DNA damage-induced cell death. Apoptosis 2000;5:491-507.
28. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808.
29. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 1989;28:6157-60.
30. Willmore E, Errington F, Tilby MJ, Austin CA. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochem Pharmacol 2002;63:1807-15.
31. Liu LF, Liu CC, Alberts BM. Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 1980;19:697-707.
32. Burden DA, Kingma PS, Froelich-Ammon SJ, et al. Topoisomerase II·etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem 1996;271:29238-44.
33. Montecucco A, Pedrali-Noy G, Spadari S, Zanolin E, Ciarrocchi G. DNA unwindingand inhibition of T4 DNA ligase by anthracyclines. Nucleic Acids Res 1988;16:3907-18.
34. Riballo E, Kuhne M, Rief N, et al. A pathway of double-strand break rejoiningdependent upon ATM, Artemis, and proteins locatingto γ-H2AX foci. Mol Cell 2004;16:715-24.
35. Jensen PB, Sorensen BS, Demant EJ, et al. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)- methanesulfon-m-anisidide in human small cell lungcance r cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 1990;50:3311-6.
36. Sorensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB, Westergaard O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. J Mol Biol 1992;228:778-86.
37. Sehested M, Jensen PB. Mappingof DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 1996;51:879-86.
38. Kaina B. DNA damage-triggered apoptosis: Critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem Pharmacol 2003;66:1547-54.
39. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 2001;20:1063-75.
40. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-76.
41. Zamzami N, Marchetti P, Castedo M, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995;181:1661-72.
42. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
43. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001;7:95-106.
44. Sullivan DM, Latham MD, Ross WE. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drugaction in human, mouse, and Chinese hamster ovary cells. Cancer Res 1987;47:3973-79.
45. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991;2:209-14.
46. Qiu J, Catapano CV, Fernandes DJ. Formation of topoisomerase IIα complexes with nascent DNA is related to VM-26-induced cytotoxicity. Biochemistry 1996;35:16354-60.
47. Cornarotti M, Tinelli S, Willmore E, et al. Drugsensitiv ity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180). Mol Pharmacol 1996;50:1463-71.
48. Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1998;1400:195-211.